AstraZeneca’s hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer — biotech CinCor Pharma — in a deal valued at $1.8 billion including potential …
Why AstraZeneca Stock Was a Winner Today
view original post